|4Feb 23, 5:17 PM ET

Francis Knuettel II 4

4 · Chromocell Therapeutics Corp · Filed Feb 23, 2024

Insider Transaction Report

Form 4
Period: 2024-02-21
Francis Knuettel II
CFO, Treas & Secty
Transactions
  • Award

    Employee Stock Option

    2024-02-212,77825,001 total(indirect: By LLC)
    Exercise: $22.68From: 2024-02-21Exp: 2033-01-10Common Stock (2,778 underlying)
Footnotes (2)
  • [F1]The securities are held by Camden Capital LLC. The Reporting Person, as the manager of Camden Capital LLC, is deemed to be a beneficial owner of these securities.
  • [F2]On January 10, 2023, Camden Capital LLC was granted stock options to purchase 2,778 shares of common stock at an exercise price of $22.68 per share, which became exercisable upon the closing of Issuer's initial public offering.

Documents

1 file
  • 4
    ownership.xmlPrimary